Markets News

Latest stock market news and real-time market analysis. Track S&P 500, Nasdaq, and Dow Jones movements, sector rotations, and breaking market events.

LightPath Technologies Soars to 52-Week High on Defense Optics Demand
Markets Daniel Marsh

LightPath Technologies Soars to 52-Week High on Defense Optics Demand

LightPath Technologies shares surged 10% to a 52-week high of $16.09 on robust defense optics orders and a $97.8 million backlog, with Q2 revenue soaring 120%.

LPTH
Plug Power's Louisiana JV Plant Reaches 90% Availability Amid Cash Flow Focus
Markets Daniel Marsh

Plug Power's Louisiana JV Plant Reaches 90% Availability Amid Cash Flow Focus

Plug Power's Louisiana hydrogen plant achieved 90% availability in Q1, producing 448.3 metric tons. Shares fell 1.3% as the company works to improve cash flow.

PLUG BLDP BE
Liberty Broadband Shares Tumble 26% as Charter's Subscriber Woes Hit Merger Value
Markets Daniel Marsh

Liberty Broadband Shares Tumble 26% as Charter's Subscriber Woes Hit Merger Value

Liberty Broadband shares plunged 26% Friday, mirroring Charter Communications' decline after the cable operator lost 120,000 internet subscribers in Q1, exceeding forecasts and pressuring the pending all-stock merger.

LBRDA LBRDK CHTR CMCSA T TMUS
Eminence Capital to Close After 27 Years, Return $5.9 Billion
Markets Daniel Marsh

Eminence Capital to Close After 27 Years, Return $5.9 Billion

Eminence Capital, founded by Ricky Sandler, is closing after 27 years, returning $5.9 billion to investors by late June amid poor returns and rising expenses.

Hims & Hers Surges on JPMorgan Upgrade and GLP-1 Expansion
Markets Daniel Marsh

Hims & Hers Surges on JPMorgan Upgrade and GLP-1 Expansion

Hims & Hers stock jumped 9% after JPMorgan gave an overweight rating and $35 target. The company now offers Eli Lilly's Zepbound and Foundayo through LillyDirect.

HIMS LLY NVO AMZN
CoreWeave CEO Cashes Out $35.8M Amid AI Cloud Rally
Markets Daniel Marsh

CoreWeave CEO Cashes Out $35.8M Amid AI Cloud Rally

CoreWeave CEO Michael Intrator sold $35.8 million in shares this week, while the company announced major customer deals and debt financing.

CRWV NVDA META MSFT
StoneCo Shares Tumble 16% After Ex-Dividend Date for $2.53 Special Payout
Markets Daniel Marsh

StoneCo Shares Tumble 16% After Ex-Dividend Date for $2.53 Special Payout

StoneCo (STNE) shares dropped 16.3% to $12.18 on Friday after trading ex-dividend for a $2.53 special cash dividend, totaling R$3.08 billion. The payout follows the sale of Linx and 2025 earnings growth.

STNE
Nasdaq Hits Record as Intel AI Outlook Fuels Chip Rally, Dow Dips
Markets Daniel Marsh

Nasdaq Hits Record as Intel AI Outlook Fuels Chip Rally, Dow Dips

The Nasdaq hit a new intraday high Friday as Intel's strong Q2 outlook sparked a broad chip rally, while the Dow slipped. Consumer sentiment hit a record low, keeping inflation worries front and center.

INTC AMD ARM NVDA QQQ SPY DIA USO GLD
Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data
Markets Daniel Marsh

Lilly's Oral Obesity Drug Foundayo Trails Novo Nordisk's Wegovy in Early Prescription Data

Eli Lilly's Foundayo prescriptions hit 3,707 in week two, well behind Novo Nordisk's Wegovy. Lilly shares dropped 4%, while Novo gained 6%. Analysts advise caution on early figures.

LLY NVO
Cheetah Net Soars on Acquisition Deal, Heavy Trading Volume
Markets Daniel Marsh

Cheetah Net Soars on Acquisition Deal, Heavy Trading Volume

Cheetah Net shares jumped on heavy volume after agreeing to buy Super International Trading for $4.98M in cash, with a $10M annual revenue target.

CTNT
FreeCast Soars on DIRECTV Multifamily Deal, Financing Risks Remain
Markets Daniel Marsh

FreeCast Soars on DIRECTV Multifamily Deal, Financing Risks Remain

FreeCast shares jumped 23.8% on a DIRECTV multifamily deal. Maxim Group initiated with Buy and $6 target. Dilution risks persist per SEC filings.

Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race
Markets Daniel Marsh

Novo Nordisk Wegovy Pill Prescriptions Surge Past Eli Lilly's Foundayo in Early Launch Race

Novo Nordisk's Wegovy pill recorded 18,410 U.S. prescriptions in its second week, far outpacing Eli Lilly's Foundayo at 3,707, according to IQVIA data. Novo shares rose, Lilly fell.

NVO LLY